St Herblain

• Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanc … Ended recruitment
  2023-510097-14-00 5 2022-04-15 Patients with MMR deficient relapse or advanced / metastatic endometri
• A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast can … Ended recruitment
  2023-503826-37-00 5 2022-02-11 Unresectable locally-advanced or metastatic HER2+ breast cancer
• Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic … Ended recruitment
  2023-506752-24-00 5 2021-08-05 Locally recurrent inoperable or metastatic HR+/HER2- breast cancer, wh
• An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cance … Ended recruitment
  2022-502600-79-00 4 2021-03-16 Endometrial cancer
• Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed … Ended recruitment
  2023-504959-27-00 5 2020-12-09 Participants with Limited Stage-Small Cell Lung Cancer, who have recei
• EMBER: A Study of LY3484356 in Patients with Breast or Other Non-Breast Cancers Ended recruitment
  2023-506785-32-00 3 2020-09-11 Breast Cancer
• Phase III randomized clinical trial for stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or withou … Ended recruitment
  2023-509049-11-00 5 2020-01-01 FIGO stage III ovarian cancer who are eligible for primary cytoreducti
• A Study of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Participants with Advanced Kidney Cancer. Ended recruitment
  2023-508264-29-00 5 2019-06-11 Advanced Renal Cell Carcinoma with Intermediate- or Poor-Risk Factors
• Prostate cancer with OligometaSTatic relapse: Combining stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736), a randomized phase II … Ended recruitment
  2024-513207-13-00 4 2019-03-21 oligometastatic hormone sensitive prostate cancer
• A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Amivantamab (JNJ61186372), a Human Bispecific EGFR and cMet Antibody, in Par … Ended recruitment
  2023-509435-11-00 1 2019-02-21 Advanced Non-Small Cell Lung Cancer
• Testing a new targeted therapy trastuzumab deruxtecan (DS-8201a) against ado-trastuzumab emtansine (T-DM1) for patients with advanced stage … Ended recruitment
  2024-511204-16-00 5 2019-01-23 Metastatic breast cancer
• Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients (PANIRINOX) Ended recruitment
  2024-510645-34-00 4 2017-06-28 RAS and B-RAF wild-type metastatic colorectal cancer. RAS and B-RAF mu
• PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection Ended recruitment
  2024-510704-37-00 5 2017-03-22 ER+/HER2- metastatic breast cancer
• A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly sympto … Ended recruitment
  2023-510453-41-00 5 2015-10-26 Castration resistant prostate cancer patients metastatic to bone.
• Phase I/II study to evaluate the efficacy and safety of PAZOPANIB in combination with TEMOZOLOMIDE as maintenance therapy in Glioblastoma pa … Ended recruitment
  2024-510960-22-00 9 2015-06-25 gliobastoma
• A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small … Halted
  2023-503298-39-00 5 2024-06-13 Metastatic Non-Small Cell Lung Cancer (mNSCLC)
• A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together with Either Pembrolizumab, Standard Therapies, or Both, in Adults with Solid T … Ended
  2023-505084-37-00 7 2025-03-17 Advanced Solid Tumors
• MK-0616 versus Comparators Study in Adults with Hypercholesterolemia Ended
  2023-504920-25-00 5 2024-08-23 Hypercholesterolemia
• A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation Ended
  2023-503223-26-00 9 2024-05-07 Advanced Solid Tumors Harboring a KRASG12C Mutation
• Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer Ended
  2023-504630-22-00 7 2024-04-19 Non-Small Cell Lung Cancer
• TACTIVE-U: An Umbrella Study to Investigate the Safety and Antitumor Activity of vepdegestrant (ARV-471) in Combination With Other Medicines … Ended
  2023-507125-41-00 9 2024-03-25 Advanced or Metastatic Breast Cancer
• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3 … Ended
  2023-505322-34-00 1 2024-01-08 Advanced or metastatic solid tumors
• A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma. Ended
  2023-503739-16-00 1 2023-12-20 Relapsed or refractory solid tumors or non-Hodgkin lymphoma
• Randomized, non-comparative, open-label early phase Ib study with OBT076 or OBT076 followed by Balstilimab in patients with Adenoid Cystic C … Ended
  2023-503270-20-00 3 2023-11-29 recurrent or metastatic Adenoid Cystic Carcinoma of the Head and Neck

Showing 73–96 of 118 trials